Filana Therapeutics (FLNA) Other Non-Current Liabilities (2010 - 2026)
Filana Therapeutics (FLNA) posted Other Non-Current Liabilities of $136000.0 for Q2 2026, up 22.52% on a QoQ basis from $111000.0 in Q1 2026, and up 72.15% year-over-year from $79000.0 in Q2 2025.
Powered by 
Analysis
Filana Therapeutics (FLNA) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Filana Therapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $136000.0 in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 72.15% year-over-year to $136000.0 in Q2 2026; TTM through Jun 2026 was $136000.0, a 72.15% increase from a year earlier, with the FY2025 full-year figure at $118000.0, up 49.37% from the prior year.
- Other Non-Current Liabilities was $136000.0 for Q2 2026 at Filana Therapeutics, up from $111000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $201000.0 in Q2 2022, with the low at $79000.0 in Q4 2024.
- Average Other Non-Current Liabilities over 5 years is $137461.5, with a median of $119000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities advanced 1.55% in 2022, then jumped 72.15% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then plunged by 59.9% to $79000.0 in 2024, then jumped by 49.37% to $118000.0 in 2025, then increased by 15.25% to $136000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $136000.0 (Q2 2026), $111000.0 (Q1 2026), and $118000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Filana Therapeutics | 38.14 Mn | 38.14 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 136,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Mar 31, 2023 | 197,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 201,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 194,000.00 |
| Sep 30, 2021 | 194,000.00 |
| Sep 30, 2011 | 434,000.00 |
| Jun 30, 2011 | 432,000.00 |
| Dec 31, 2010 | 431,000.00 |